Dear EURETINA Members, A very warm welcome to the November 21st, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »November 21st, 2024 “EURETINA-Brief”© Issue No. 304
Researchers at the Department of Ophthalmology, and the Center for Visual Science, University of Rochester, New York, have reported a study using induced pluripotent stem… Read More »A novel induced pluripotent stem cell model shows a mechanistic defect and potential therapy for AMD and related macular dystrophies.
Clinical researchers at the Department of Ophthalmology, Bascom Palmer Eye Institute, in the University of Miami, Florida, have presented an update on clinical trial endpoints… Read More »An update of clinical trial endpoints provide a dynamic trial environment across a range of inherited retinal degenerations (IRDs).
Life sciences company AlloVir, Inc. (NASDAQ: ALVR), based in Watham, Mass. and Palo Alto, California, have announced a merger agreement to combine with Kalaris Therapeutics… Read More »AlloVir and Kalaris Therapeutics have announced a merger to support a new anti-VEGF opportunity.
Dear EURETINA Members, A very warm welcome to the November 7th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »November 7th, 2024 “EURETINA-Brief”© Issue No. 303
Researchers at the Ophthalmic Genetics and Visual Function Branch, National Eye Institute, Bethesda, Maryland, USA have reported a genetic association between UBAP1L variants and retinal… Read More »A novel IRD candidate gene, UBAP1L, provides a loss-of-function causing macular, cone and cone-rod dystrophy.
Clinical researchers at the Center for Hereditary Retinal Degenerations, Scheie Eye Institute, University of Pennsylvania, Philadelphia, have published the results of a Phase 1/2 study… Read More »Dose escalation study of ASTN-101 (AAV5-GUCY2D) for LCA1 patients provide improvement in FST and BCVA (Phase 1/2).
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), based in Watertown, Massachusetts, have announced positive interim 16-week data for an ongoing Phase 2 “VERONA” clinical trial, evaluating “DURAVYU”… Read More »EyePoint Pharmaceuticals announce interim results from a Phase 2 EYP-1901 treatment (a tyrosine kinase inhibitor with a sustained delivery insert) for DME patients.
Dear EURETINA Members, A very warm welcome to the October 24th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »October 24th, 2024 “EURETINA-Brief”© Issue No. 302
Researchers at the University of New South Wales, Sydney, Australia, have reported a new study indicating that RPE curvature may provide a promising quantitative outer… Read More »A new research study on RPE curvature may provides a promising quantitative biomarker for late AMD.
